A Pharmacokinetic Study of HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function.

Phase 1 Not yet recruiting 32 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a two-part single-center, open-label, parallel, single-dose pharmacokinetic study of HS-10504 in participants with hepatic impairment and normal hepatic function.

Timeline

Start: 2026-09-30
Primary completion: 2027-09-25
Completion: 2027-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HS-10504	Unknown	400 mg	Oral

Indications

No indication recorded.